RegenoCELL to open new facility in Panama for treatment of congestive heart failure

Jul 30 2011

RegenoCELL Therapeutics, Inc. (OTCBB: RCLL) , a leader in adult stem cell therapy, is pleased to announce it is planning to open another state of the art facility in Panama for patients to be treated for congestive heart failure and peripheral artery disease with its autologous stem cell therapy.

The Company's treatment for congestive heart failure when cleared for importation into Panama will be administered at the Hospital Sante Fe.  Panama is a convenient location for patients living in the United States, Central and South America and when the treatment is cleared for importation will offer patients an additional location where the company's autologous stem cell treatments will be permitted.

Since 2005, the Company's stem cell therapy has successfully treated over 500 patients.  The typical patient is suffering from congestive heart failure with no treatment options and 3 to 6 months to live.  Over 5 years later patents initially treated are leading active and fulfilling lives.

SOURCE RegenoCELL Therapeutics, Inc.